SCHEMBL13765769

SCHEMBL13765769

CSc1nc(-c2ccc3ccccc3c2)c2nc[nH]c2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
HSP90AB1 P08238 6/20 0.38
MAPK9 P45984 2/20 0.37
MAPK10 P53779 2/20 0.37
MAPK8 P45983 1/20 0.37
PIK3CD O00329 1/20 0.36
ABL1 P00519 1/20 0.36
EGFR P00533 1/20 0.36
HCK P08631 1/20 0.36
SRC P12931 1/20 0.36
KDR P35968 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
MTOR P42345 1/20 0.36
PIK3CG P48736 1/20 0.36
EPHB4 P54760 1/20 0.36
PRKDC P78527 1/20 0.36
AR P10275 1/20 0.35
KDM4E B2RXH2 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13765754 0.80 CYP11B1 (0.41) CYP11B1CYP11B2MAPK9MAPK10MAPK8
SCHEMBL4084818 0.76 HSP90AB1 (0.65) HSP90AB1KDM4ECYP1A2
SCHEMBL14002327 0.72 MEN1 (0.54) HSP90AB1KDM4EALDH1A1MAPTHPGD
SCHEMBL3002841 0.71 LMNA (0.46) MAPK9MAPK8ABL1HCKSRC
SCHEMBL28163166 0.70 KDM4E (0.56) CYP11B1CYP11B2MAPK9MAPK10MAPK8
SCHEMBL4090407 0.70 HSP90AB1 (0.68) HSP90AB1ALDH1A1MAPTHTTCYP1A2
SCHEMBL4094400 0.70 HSP90AB1 (0.55) HSP90AB1KDM4ECYP1A2
SCHEMBL13765768 0.70 HSP90AB1 (0.68) HSP90AB1KDM4EMAPT
SCHEMBL763254 0.70 MAP3K5 (0.39) HSP90AB1KDM4EALDH1A1MAPTHPGD
SCHEMBL14249666 0.69 CHRNA7 (0.36) CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer HSP90AA1, HSP90AB1, HSP90AB2P CYP11B1 2438/4885CYP11B2 2619/4885HSP90AB1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.